Question explored with the scientific record
Conversation so far
- 1 Is ivermectin good for treating cancer?
- 2 How does ivermectin compare with standard cancer drugs in evidence?
Answered on this page ↓
How does ivermectin compare with standard cancer drugs in evidence?
The short version: standard cancer drugs have been tested in thousands of human trials with hard endpoints like survival. Ivermectin has none of that.
The evidence for standard cancer drugs is human clinical trial data. Trastuzumab deruxtecan improved overall survival from 8.4 to 12.5 months in HER2-positive gastric cancer patients in a randomized trial [14]. Cetuximab added to chemotherapy improved response rates from 39% to 47% in metastatic colorectal cancer, though overall survival benefit varied [20]. These are phase III trials with hundreds of patients, hard endpoints, and known toxicity profiles.
The evidence for ivermectin in cancer is entirely preclinical. It kills cancer cells in lab dishes through several mechanisms: blocking AKT/mTOR and Wnt signaling, inducing mitochondrial dysfunction, and triggering immunogenic cell death [8, 12, 28, 29]. One study showed it converted cold breast tumors to hot tumors in mice, synergizing with immune checkpoint blockade [2]. Another showed intranasal ivermectin nanocapsules reduced glioma size by 70% in rats [11]. But these are all animal models. The human data that exists is about parasitic infections in cancer patients, not about treating cancer itself [1, 3, 5, 6, 7, 9].
| Comparison | Ivermectin | Standard cancer drugs |
|---|---|---|
| Human RCTs with survival endpoints | None | Hundreds |
| Best evidence type | Mouse xenografts, cell lines | Phase III randomized trials |
| Toxicity data at anticancer doses | Not established | Well-characterized |
| FDA/EMA approval for cancer | No | Yes for many |
The gap is not subtle. Most drugs that work in mice fail in humans. The doses that kill cancer cells in these studies (IC50 6-16 µM) may not be reachable in human tumors without toxicity [8, 12]. No randomized controlled trial has tested ivermectin against any standard cancer drug in humans.
My call: standard cancer drugs have proven human evidence; ivermectin has none. Confidence: high.
Sources used 14
-
Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador
This study investigates the use of ivermectin as an alternative treatment for cancer in rural areas of Loja, Ecuador, revealing that a significant percentage of cancer patients self-medicate with this antiparasitic drug despite a lack of scientific endorsement for its efficacy i…
DOI: 10.3390/nursrep13010030 -
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
This study demonstrates that ivermectin can convert cold breast tumors into hot tumors by inducing immunogenic cell death and enhancing T cell infiltration, thereby synergizing with immune checkpoint blockade for improved treatment outcomes.
DOI: 10.1038/s41523-021-00229-5 -
Strongyloides stercoralis larvae in the urine of a patient with transitional cell carcinoma of the bladder: a case report
A Nigerian case report describing disseminated Strongyloides stercoralis infection with larvae detected in the urine of a 60-year-old man with transitional cell carcinoma of the bladder, treated with ivermectin, who died within a week, highlighting the need to suspect strongyloi…
DOI: 10.1007/s12639-018-1051-6 -
A Case Report of Disseminated Strongyloidiasis Following Chemoradiotherapy for Lung Cancer in a Patient Living in a Non-endemic Area in Japan
This case report documents HTLV-1-associated disseminated Strongyloides stercoralis infection developing after chemoradiotherapy for lung cancer in a non-endemic area of Japan, successfully treated with daily ivermectin followed by six months of intermittent dosing, highlighting…
DOI: 10.2169/internalmedicine.5829-25 -
Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated strongyloidiasis and septic shock
This study reports the successful treatment of a 56-year-old immunosuppressed patient with disseminated strongyloidiasis and septic shock using a combination of parenteral and enteral ivermectin.
DOI: 10.1007/s00134-005-2725-y -
Demodex inflammatory eruption due to epidermal growth factor receptor inhibitor therapy
This case study describes a patient who developed a Demodex inflammatory eruption following epidermal growth factor receptor inhibitor therapy, highlighting the need for alternative treatments when traditional therapies fail.
DOI: 10.1111/bjd.14202 -
Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway
Ivermectin inhibits ESCC proliferation in vitro and in vivo by inducing mitochondrial dysfunction, ROS accumulation, NF-κB inhibition, and apoptosis via the mitochondrial pathway.
DOI: 10.1186/s12885-021-09021-x -
Filariasis of the Axilla in a Patient Returning from Travel Abroad: A Case Report
A rare case report of filariasis presenting as a right axillary breast-axillary mass in a traveler, with histology identifying a parasite of the genus Dirofilaria, supportive serology, ivermectin treatment, and emphasis on interdisciplinary collaboration across breast, pathology…
DOI: 10.1159/000345471 -
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression
This study demonstrates nose-to-brain delivery of ivermectin nanocarriers (polymeric nanocapsules and mesoporous silica particles) to suppress glioma growth in a rat model, with intranasal polymeric nanocapsules significantly reducing tumor size and improving histology at a clin…
DOI: 10.1021/acsbiomaterials.5c00642 -
Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells
This study investigates the synergistic effects of ivermectin and pitavastatin on ovarian cancer cell lines, demonstrating that their combination enhances anti-cancer activity and may reduce the required dosage of pitavastatin.
DOI: 10.3390/diseases11010049 -
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
This study demonstrates that trastuzumab deruxtecan significantly improves objective response rates and overall survival compared to standard chemotherapy in patients with HER2-positive advanced gastric cancer who have previously received multiple treatments.
DOI: 10.1056/NEJMoa2004413 -
Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation
Cetuximab added to standard chemotherapy improves response rates and progression-free survival in EGFR-expressing metastatic colorectal cancer, with KRAS wild-type status predicting better outcomes, though overall survival benefits vary across trials.
DOI: 10.21518/2079-701x-2018-19-32-41 -
Old wine in new bottles: Drug repurposing in oncology
A comprehensive narrative review detailing how eight non-oncologic drugs (artesunate, aspirin, cimetidine, doxycycline, ivermectin, metformin, rapamycin, and thalidomide) have demonstrated anticancer activity across in vitro, in vivo, and limited clinical contexts, outlining the…
DOI: 10.1016/j.ejphar.2019.172784 -
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Ivermectin triggers autophagy through AKT/mTOR inhibition in glioma cells; autophagy protects against IVM-induced apoptosis in vitro, and combining with chloroquine enhances anti-glioma effects in vivo.
DOI: 10.1042/bsr20192489